Advanced search

Showing result 1 - 5 of 27 swedish dissertations matching the above criteria.

2. 1. Design and Synthesis of Serine and Aspartic Protease Inhibitors

   Author : Fredrik Wångsell; Ingemar Kvarnström; Olle Karlsson; Linköpings universitet; []
   Keywords : NATURVETENSKAP; NATURAL SCIENCES; organic chemistry; organic synthesis; metathesis; HCV; NS3; protease; proline isosteres; inhibitor; aspartic protease inhibitors; hydroxyethylene; Organic synthesis; Organisk syntes;

   Abstract : This thesis describes the design and synthesis of compounds that areintended to inhibit serine and aspartic proteases. The first part of the text deals with preparation of inhibitors of the hepatitis C virus (HCV) NS3 serine protease. Hepatitis C is predominantly a chronic disease that afflicts about 170 million people worldwide. READ MORE

4. 2. Peptidomimetic Enzyme Inhibitors : Targeting M. tuberculosis Ribonucleotide Reductase and Hepatitis C Virus NS3 Protease

   Author : Johanna Nurbo; Anders Hallberg; Anders Karlén; Anja Sandström; Per Arvidsson; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; enzyme inhibitor; peptidomimetics; structure-activity relationship; tuberculosis; ribonucleotide reductase; hepatitis C virus; NS3 protease; Pharmaceutical chemistry; Farmaceutisk kemi; Medicinal Chemistry; Läkemedelskemi;

   Abstract : This thesis focuses on the design and synthesis of inhibitors targeting Mycobacterium tuberculosis ribonucleotide reductase (RNR) and hepatitis C virus (HCV) NS3 protease; enzymes that have been identified as potential drug targets for the treatment of tuberculosis and hepatitis C, respectively. Small peptides have been recognized as inhibitors of these enzymes. READ MORE

5. 3. Design and Synthesis of Aspartic and Serine Protease Inhibitors : Targeting the BACE-1 and the HCV NS3 Protease

   Author : Fredrik Wångsell; Mats Larhed; Jari Yli-Kauhaluoma; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alzheimer s disease; BACE-1; transition state mimetic; tertiary hydroxyl group; hydroxyethylene; statine; hydroxyethylamine; hepatitis C; HCV NS3; bioisostere; protease inhibitor.; Pharmaceutical chemistry; Läkemedelskemi; Medicinal Chemistry; Läkemedelskemi;

   Abstract : This thesis describes work done to design and synthesize protease inhibitors, with the intention of developing therapeutic agents for Alzheimer’s disease (AD) and the chronic liver condition caused by infection of the hepatitis C virus (HCV). AD is the most common form of dementia, and HCV infection is the primary reason for liver transplantation in industrialized countries. READ MORE

6. 4. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors Incorporating a P2 Cyclopentane-Derived Scaffold

   Author : Marcus Bäck; Anja Sandström; Linköpings universitet; []
   Keywords : NATURVETENSKAP; NATURAL SCIENCES; HCV; NS3 protease; Proline mimic; Cyclopentane-derived scaffold; Linear inhibitors; Macrocyclic inhibitors; Organic synthesis; Organisk syntes;

   Abstract : This thesis describes the design, synthesis and structure-activity relationships analysis of potential inhibitors targeting the hepatitis C virus (HCV) NS3 protease. Also discussed is the disease caused by HCV infection and the class of enzymes known as proteases. READ MORE

7. 5. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors : Targeting Different Genotypes and Drug-Resistant Variants

   Author : Anna Karin Belfrage; Anja Sandström; Ulf Ellervik; Uppsala universitet; []
   Keywords : NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; hepatitis C virus; HCV; NS3 protease inhibitors; structure-activity relationship; 2 1H -pyrazinone; quinazoline; resistance; Pd catalysis; Medicinal Chemistry; Läkemedelskemi; Farmaceutisk vetenskap; Pharmaceutical Science;

   Abstract : Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. READ MORE